Global Retirement Partners LLC Buys Shares of 6,773 TransMedics Group, Inc. $TMDX

Global Retirement Partners LLC bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 6,773 shares of the company’s stock, valued at approximately $450,000.

Other hedge funds have also recently modified their holdings of the company. Harvest Fund Management Co. Ltd bought a new position in shares of TransMedics Group during the third quarter valued at $29,000. Allworth Financial LP increased its holdings in TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after buying an additional 113 shares in the last quarter. Parallel Advisors LLC increased its holdings in TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after buying an additional 83 shares in the last quarter. Ascentis Independent Advisors purchased a new position in TransMedics Group in the 1st quarter worth about $30,000. Finally, North Star Investment Management Corp. bought a new position in TransMedics Group during the 1st quarter valued at about $30,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

TMDX has been the topic of a number of recent analyst reports. Zacks Research downgraded shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Weiss Ratings downgraded shares of TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, July 28th. Canaccord Genuity Group restated a “buy” rating and set a $124.00 price objective on shares of TransMedics Group in a research report on Tuesday, June 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Finally, UBS Group cut their target price on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a research report on Wednesday, August 5th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, TransMedics Group currently has a consensus rating of “Hold” and an average target price of $124.18.

Insider Activity

In related news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

TransMedics Group Stock Up 3.6%

TMDX stock opened at $93.97 on Thursday. The company has a market cap of $3.25 billion, a price-to-earnings ratio of 24.16 and a beta of 1.90. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. The business’s 50-day moving average is $76.71 and its two-hundred day moving average is $95.63. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. During the same quarter in the prior year, the firm earned $0.92 earnings per share. The company’s revenue for the quarter was up 20.7% compared to the same quarter last year. As a group, analysts forecast that TransMedics Group, Inc. will post 1.47 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.